Ocular allergy: update on clinical trials.
暂无分享,去创建一个
[1] E. Takamura,et al. Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic Dermatitis , 2019, Current eye research.
[2] L. Ziska,et al. Associations between alteration in plant phenology and hay fever prevalence among US adults: Implication for changing climate , 2019, PloS one.
[3] I. Wang,et al. Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis , 2019, Graefe's Archive for Clinical and Experimental Ophthalmology.
[4] R. Mösges,et al. Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season , 2019, The World Allergy Organization journal.
[5] P. Joly,et al. Tacrolimus ointment in the management of atopic keratoconjunctivitis. , 2019, Journal francais d'ophtalmologie.
[6] L. Bielory,et al. Emerging Therapeutics for Ocular Surface Disease , 2019, Current Allergy and Asthma Reports.
[7] E. Meier,et al. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects , 2019, Clinical ophthalmology.
[8] P. Georgopoulos,et al. Development of a semi-mechanistic allergenic pollen emission model. , 2019, The Science of the total environment.
[9] Takahiro Minami,et al. In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses , 2019, PloS one.
[10] S. Nakowitsch,et al. Pharmacokinetics of topically applied tacrolimus dissolved in Marinosolv, a novel aqueous eye drop formulation , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[11] A. Murakami,et al. Dietary ω-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] S. Asilsoy,et al. Efficacy of allergen-blocker mechanical barrier gel on symptoms and quality of life in patients with allergic rhinitis , 2018, European Archives of Oto-Rhino-Laryngology.
[13] T. S. Tat. Adherence to Subcutaneous Allergen Immunotherapy in Southeast Turkey: A Real-Life Study , 2018, Medical science monitor : international medical journal of experimental and clinical research.
[14] E. Meier,et al. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model , 2018, Clinical ophthalmology.
[15] F. Cavarzeran,et al. Efficacy and Tolerability of Ketotifen in the Treatment Of Seasonal Allergic Conjunctivitis: Comparison between Ketotifen 0.025% and 0.05% Eye Drops , 2018, Ocular immunology and inflammation.
[16] P. Demoly,et al. An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France , 2018, Allergy, Asthma & Clinical Immunology.
[17] D. Zadok,et al. Mini-monoka stenting for patients with perennial allergic conjunctivitis , 2018, Orbit.
[18] H. Nolte,et al. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. , 2018, Allergology international : official journal of the Japanese Society of Allergology.
[19] E. Valovirta,et al. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis. , 2018, Clinical therapeutics.
[20] R. Mösges,et al. A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy , 2017, Allergy.
[21] S. Choi,et al. Intralymphatic Immunotherapy Alleviates Allergic Symptoms During Allergen Exposure in Daily Life , 2017, Allergy, asthma & immunology research.
[22] L. Klimek,et al. Ultra‐short‐course booster is effective in recurrent grass pollen‐induced allergic rhinoconjunctivitis , 2017, Allergy.
[23] R. O’Hehir,et al. Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis , 2017, The Journal of allergy and clinical immunology.
[24] T. Sugahara,et al. Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge. , 2017, Investigative ophthalmology & visual science.
[25] R. Van Ree,et al. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation , 2017, International Archives of Allergy and Immunology.
[26] M. Christman,et al. Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial. , 2017, The American journal of clinical nutrition.
[27] R. Kumari,et al. Tacrolimus versus Cyclosporine- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis. , 2017, Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH.
[28] A. Concheiro,et al. Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis. , 2016, Acta biomaterialia.
[29] W. Carr,et al. Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief , 2016, Allergy & rhinology.
[30] Anita K. Bakrania,et al. Combination treatment for allergic conjunctivitis - Plant derived histidine decarboxylase inhibitor and H1 antihistaminic drug. , 2015, Experimental eye research.
[31] T. Kündig,et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials , 2015, Allergy.
[32] R. Jacobs,et al. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[33] K. Fukuda,et al. Prevention of allergic conjunctivitis in mice by a rice-based edible vaccine containing modified Japanese cedar pollen allergens , 2015, British Journal of Ophthalmology.
[34] M. Blaiss,et al. Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. , 2014, Allergy and asthma proceedings.
[35] J. Wolffsohn,et al. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. , 2014, Ophthalmology.
[36] L. Bielory,et al. Emerging therapies in allergic conjunctivitis and dry eye syndrome , 2013, Expert opinion on pharmacotherapy.
[37] F. Horak,et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial , 2012, Allergy.